Skip to content
OpenCapital
Get started

Dianthus Therapeutics DNTH EBIT

EBIT at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$84.15M-13.1%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$3.65M+81.1%
Johnson & Johnson logo
Johnson & JohnsonJNJ
——
Amgen logo
AmgenAMGN
——
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
——
TG Therapeutics logo
TG TherapeuticsTGTX
——

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$4.51B+662%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0×0.0×
Current ratio29.3×+13.3×

Where this comes from

Calculated from Dianthus Therapeutics’s reported figures.

−$46.5Moperating income=-$46.53M

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dianthus Therapeutics's EBIT?
Dianthus Therapeutics (DNTH) reported EBIT of -$46.53M in Q1 2026.
How has Dianthus Therapeutics's EBIT changed year-over-year?
Dianthus Therapeutics's EBIT decreased by 40.3% year-over-year, from -$33.18M to -$46.53M.
What is the long-term trend for Dianthus Therapeutics's EBIT?
Over 3 years (2021 to 2024), Dianthus Therapeutics's EBIT has grown at a 10.9% compound annual growth rate (CAGR), from -$74.69M to -$101.86M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.